Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for prostate cancer
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on prostate cancer or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on prostate cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com
Might definitive local therapy of the primary tumor improve the survival benefits of metastatic prostatecancer? -evidence from a meta-analysis. With the successful application of local therapy (LT) of the primary tumor in other metastatic disease and the demonstration of their better survival benefits, the traditionally seldom involved role of LT for metastatic prostatecancer (mPCa) had gained a lot of interest. Hence, this meta-analysis was conducted to clarify its efficacy in mPCa.A (...) survival (OS) (pooled HR =0.53, 95% CI: 0.47 to 0.61, I2=59.7%, P=0.015), decreased cancer-specific mortality (CSM) (pooled HR =0.42, 95% CI: 0.34 to 0.51, I2=63.1%, P=0.004) and lower all-cause mortality (ACM) (pooled HR =0.37, 95% CI: 0.31 to 0.45, I2=49.4%, P=0.115), compared with no local therapy (NLT). In subsequent stratified analysis, RP or RT was respectively linked to longer OS (pooled HR =0.49, 95% CI: 0.44 to 0.54, I2=0.0%, P=0.741; pooled HR =0.64, 95% CI: 0.56 to 0.72, I2=15.4%, P=0.306
The impact of 5-alpha-reductase inhibitors on mortality in a prostatecancer chemoprevention setting: a meta-analysis. This study aims to evaluate the impact of 5-alpha-reductase inhibitors (5ARI) for prostatecancer (PCa) primary prevention on specific and overall mortality (primary outcomes), the incidence of PCa diagnosis and disease aggressiveness (secondary outcomes).We searched MEDLINE, EMBASE, Cochrane, ClinicalTrials and BVS through April 2018 according to the Preferred Reporting Items (...) PCa diagnosis (RR 1.06 95% CI 0.72-1.56). We identified a relative risk reduction of 24% in moderate-grade PCa diagnosis (RR 0.76 95% CI 0.59-0.98) and low-grade PCa diagnosis (RR 0.76 95% CI 0.59-0.97) Also, a reduction of 26% in overall PCa diagnosis was observed in the RCT subgroup analysis (RR 0.74 95% CI 0.65-0.84).5ARI significantly reduced the risk of being diagnosed with PCa, not increasing high-grade disease, overall or cancer-specific mortality. Due to the relatively short mean follow-up
= 1.50-4.47). EPE, larger tumor size, greater tumor volume, presence of metastatic pelvic lymph nodes (LNs), and presence of SVI were significant risk factors for metastasis (pooled HRs = 1.12-11.96). Pelvic LN metastasis was significantly predictive of cancer-specific mortality (HR = 4.45 [95% CI, 1.30-15.23]). CONCLUSION. Several pretreatment MRI findings were significant prognostic factors in patients with prostatecancer who underwent RT. (...) Prognostic Value of Pretreatment MRI in Patients With ProstateCancer Treated With Radiation Therapy: A Systematic Review and Meta-Analysis. OBJECTIVE. Despite a substantial increase in the use of MRI for pretreatment evaluation of prostatecancer, its prognostic value in patients undergoing radiation therapy (RT) is not well known. Therefore, the purpose of this study was to systematically review the literature and perform a meta-analysis on the prognostic value of pretreatment MRI in patients
Prognostic significance of E-cadherin expression in prostaticcarcinoma: A protocol for systematic review and meta-analysis. Increasing studies were performed to explore the prognostic value of E-cadherin in prostaticcarcinoma, however, with inconsistent results. Hence, this systematic review is aimed to evaluate the prognostic role of E-cadherin in patients with prostaticcarcinoma (PCa).A comprehensive literature search in all available databases will be conducted to identify eligible (...) studies. We will employ hazard ratios (HRs) and 95% confidence intervals (95% CIs) to estimate the correlations between E-cadherin expression and overall survival (OS), disease-free survival (DFS), relapse-free survival (RFS), progression-free survival (PFS) and clinicopathological features. Meta-analysis will be performed using Review Manager (Revman) 5.3.5 software (Cochrane Community, London, United Kingdom) and STATA 14 software (version 14.0; Stata Corp, College Station, TX).This study
Metastatic castration-resistant prostatecancer: Academic insights and perspectives through bibliometric analysis. In recent years, metastatic castration-resistant prostatecancer (MCRPC) and studies related to MCRPC have drawn global attention. The main objective of this bibliometric study was to provide an overview of MCRPC, explore clusters and trends in research and investigate the future direction of MCRPC research.A total of 4089 publications published between 1979 and 2018 were retrieved (...) from the Web of Science (WoS) Core Collection database. Different aspects of MCRPC research, including the countries/territories, institutions, journals, authors, research areas, funding agencies and author keywords, were analyzed.The number of annual MCRPC publications increased rapidly after 2010. American researchers played a vital role in this increase, as they published the most publications. The most productive institution was Memorial Sloan Kettering Cancer Center. De Bono, JS (the United
Association of NAD (P) H Quinine Oxidoreductase 1 rs1800566 Polymorphism with Bladder and ProstateCancers - a Systematic Review and Meta-Analysis. Number of studies has been performed to investigate the association of NAD (P) H quinine oxidoreductase 1 (NQO1) rs1800566 polymorphism with risk of bladder and prostatecancers, but presented inconsistent results. Therefore, we performed a meta-analysis to provide a comprehensive data on the association of NQO1 rs1800566 polymorphism with bladder (...) and prostate cancers.All eligible studies were identified in PubMed, Google Scholar, EMBASE, and China National Knowledge Infrastructure databases before June 01, 2019.A total of 22 case-control studies including 15 studies with 4,413 cases and 4,275 controls on bladder cancer and 7 studies with 762 cases and 1,813 controls on prostatecancer were selected. Overall, pooled data showed that the NQO1 rs1800566 polymorphism was significantly associated with an increased risk of bladder cancer (T vs. C
, 95% CI 0.24-0.79) showed statistically significant lower rates of high grade adverse events compared to docetaxel.Treatment with androgen receptor axis targeted therapies combined with androgen deprivation therapy in patients with hormone sensitive prostatecancer did not offer a statistically significant advantage in overall survival compared to the standard, docetaxel. However, it was associated with a lower disease progression rate. Moreover, apalutamide and enzalutamide offer a better safety (...) New Antiandrogen Compounds Compared to Docetaxel for Metastatic Hormone Sensitive ProstateCancer: Results from a Network Meta-Analysis. Docetaxel represent the standard of care in patients with metastatic, hormone sensitive prostatecancer. However, androgen receptor axis targeted therapies have also been shown to be effective. We aimed to analyze findings in randomized controlled trials investigating first-line treatment for hormone sensitive prostate cancer.We systematically reviewed
Cardiovascular Effects of Androgen Deprivation Therapy in ProstateCancer: Contemporary Meta-Analyses. Androgen deprivation therapy is a cornerstone of prostatecancer treatment. Pharmacological androgen deprivation includes gonadotropin-releasing hormone agonism and antagonism, androgen receptor inhibition, and CYP17 (cytochrome P450 17A1) inhibition. Studies in the past decade have raised concerns about the potential for androgen deprivation therapy to increase the risk of adverse (...) between androgen deprivation therapy use and cardiovascular disease, and randomized controlled trials, which do not show these associations reproducibly.
finasteride use and high-grade prostatecancer was also observed with combined ORs of 2.10 [1.85, 2.38].This study confirms that finasteride significantly reduced the risk of prostatecancer; however, the malignant degree of prostatecancer was increased. Studies with larger sample sizes are needed to better clarify the correlation between finasteride use and prostatecancer. (...) Association of finasteride with prostatecancer: A systematic review and meta-analysis. The ProstateCancer Prevention Trial has shown a protective effect of finasteride on prostatecancer, but it also showed that finasteride can increase the risk of high-grade prostatecancer. Several studies have investigated the relationship between finasteride and prostatecancer, but these studies have shown inconsistent results.The protocol was approved by the institutional review board of each study
Is There a Benefit of Addition Docetaxel, Abiraterone, Celecoxib, or Zoledronic Acid in Initial Treatments for Patients Older Than 70 Years With Hormone-sensitive Advanced ProstateCancer? A Meta-analysis. Results from large randomized controlled trials combining docetaxel, abiraterone, celecoxib, or bisphosphonates with androgen deprivation therapy (ADT) in hormone-sensitive prostatecancer have emerged. However, in our knowledge, few data are available in patients older than 70 years (...) . Therefore, we undertook a meta-analysis of all published phase III studies.We performed a PubMed search using the keywords: "hormone sensitive prostatecancer," "phase III studies," "docetaxel," "abiraterone," "celecoxib," and "bisphosphonates." We also screened American Society of Clinical Oncology and European Society for Medical Oncology proceedings. Combination therapies were compared with ADT alone. The efficacy outcomes were overall survival (OS) and progression-free survival (PFS). Hazard ratios
Barriers and facilitators to physical activity in men with prostatecancer: A qualitative and quantitative systematic review. Existing research indicates that moderate-to-vigorous physical activity (PA) alleviates treatment side effects and is associated with survival in men with prostatecancer. We aimed to ascertain the state of research investigating barriers and facilitators to PA in men with prostatecancer and synthesise existing qualitative research on this topic.A systematic review (...) of qualitative and quantitative studies was conducted. MEDLINE, Embase, PsycINFO, Web of Knowledge, CINAHL, PEDro, OATD, and WorldCat were searched to June 2019 for quantitative studies investigating causes or predictors of PA or qualitative studies describing patient-reported barriers/facilitators to PA, amongst men with prostatecancer of any stage. Thirty-two studies (n = 17 quantitative; n = 15 qualitative) were included from 3698 screened articles.Heterogeneity and unsystematic reporting of quantitative
The effectiveness of lifestyle interventions to reduce side effects of androgen deprivation therapy for men with prostatecancer: a systematic review. The aim of this review is to systematically review randomized controlled trials on lifestyle interventions on PCa patients undergoing androgen deprivation therapy.A literature search was conducted using the electronic databases Medline and PubMed. To be eligible, studies had to be randomized controlled trials (RCTs) that focused on side effects
Dietary Glycemic Index and Glycemic Load and the Risk of ProstateCancer: An Updated Systematic Review and Dose-Response Meta-Analysis. A meta-analysis in 2015 revealed no significant association between glycemic index (GI), glycemic load (GL), and prostatecancer. Moreover, until now, no study has examined the dose-response association of GI, GL, and prostatecancer yet. The online databases were searched by two independent researchers for relevant publications up to Jan. 2019, using relevant (...) keywords. Nine studies including five prospective and four case-control studies were included in the current systematic review and meta-analysis. These studies have included 290,911 individuals. We found a significant positive dose-response association between dietary GI and prostatecancer (Pnonlinearity = 0.03). Comparing individuals in the highest category of GI with those in the lowest category, no significant association was found between GI and prostatecancer (combined effect size: 1.08, 95% CI
pathologic entity.Thirteen studies with a total of 20 patients (mean age: 70.3, range 43-87) were included in our review. Seventeen patients harbored primary LCNEC of the prostate, of which 9 patients were diagnosed with de novo carcinoma, and 8 patients were with a history of prostaticadenocarcinoma treated with hormonal therapy (mean duration: 2.9 years, range 2-5). The other 3 patients were diagnosed with metastatic LCNEC originating from lung (2 cases) and bladder (1 case). All patients met (...) the diagnostic criteria of the typical morphological features as well as immunohistochemical staining results. Nearly all primary de novo LCNEC of the prostate were at a late stage at initial diagnosis. The pattern of distant metastasis resembled that of prostaticadenocarcinoma with the most common sites as bone spread (8/16, 50%). Most patients received systematic chemotherapy after diagnosis; however, the prognosis remained poor and patients deteriorated rapidly but with exception. Three reported cases
No association between three polymorphisms (rs1800629, rs361525 and rs1799724) in the tumor necrosis factor-Î± gene and susceptibility to prostatecancer: a comprehensive meta-analysis. Inflammation is one of the factors associated with prostatecancer. The cytokine tumor necrosis factor-alpha (TNF-α) plays an important role in inflammation. Several studies have focused on the association between TNF-α polymorphisms and prostatecancer development. Our meta-analysis aimed to estimate (...) the association between TNF-α rs1800629 (- 308 G/A), rs361525 (- 238 G/A) and rs1799724 polymorphisms and prostatecancer risk.Eligible studies were identified from electronic databases (PubMed, Embase, Wanfang and CNKI) using keywords: TNF-α, polymorphism, prostatecancer, until Nov 15, 2019. Odds ratios (ORs) with 95% confidence intervals (CIs) were applied to determine the association from a quantitative point-of-view. Publication bias and sensitivity analysis were also applied to evaluate the power
A Systematic Review and Network Meta-analysis of Novel Androgen Receptor Inhibitors in Non-metastatic Castration-resistant ProstateCancer. Among men with high-risk non-metastatic castrate-resistant prostatecancer (nmCRPC), we used network meta-analysis to compare non-steroidal anti-androgens (NSAAs) and stratified class-level meta-analysis to identify subgroups with particular benefit from NSAAs with androgen deprivation therapy versus androgen deprivation therapy alone.We performed (...) a systematic review of phase III parallel-group randomized controlled trials in adult men with nmCRPC. Primary outcome was metastasis-free survival (MFS). Secondary outcomes included overall survival (OS), prostate-specific antigen (PSA) progression-free survival (PFS), and rates of grade 3 to 4 adverse events (AEs). We assessed class-level effects using random effects models; effect modification owing to subgroup effects using random-effects models to pool study-level differences; and comparative outcomes
Patient-Centered Outcomes From Multiparametric MRI and MRI-Guided Biopsy for ProstateCancer: A Systematic Review. To identify and characterize patient-centered outcomes (PCOs) relating to multiparametric MRI (mpMRI) and MRI-guided biopsy as diagnostic tests for possible prostate cancer.Medline via OVID, EMBASE, PsycInfo, and the Cochrane Central register of Controlled Trials (CENTRAL) were searched for relevant articles. Hand searching of reference lists and snowballing techniques were
, randomised study, we recruited men with biopsy-proven prostatecancer and high-risk features at ten hospitals in Australia. Patients were randomly assigned to conventional imaging with CT and bone scanning or gallium-68 PSMA-11 PET-CT. First-line imaging was done within 21 days following randomisation. Patients crossed over unless three or more distant metastases were identified. The primary outcome was accuracy of first-line imaging for identifying either pelvic nodal or distant-metastatic disease (...) Prostate-specific membrane antigen PET-CT in patients with high-risk prostatecancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Conventional imaging using CT and bone scan has insufficient sensitivity when staging men with high-risk localised prostatecancer. We aimed to investigate whether novel imaging using prostate-specific membrane antigen (PSMA) PET-CT might improve accuracy and affect management.In this multicentre, two-arm